



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Hellyer, T. P., Anderson, N. H., Parker, J., Dark, P., Van Den Broeck, T., Singh, S., McMullan, R., Agus, A. M., Emerson, L. M., Blackwood, B., et al (2016). Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'. *Trials*, 17(1), 465. doi: 10.1186/s13063-016-1594-8

This is the published version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://city-test.eprints-hosting.org/id/eprint/22718/>

**Link to published version:** <https://doi.org/10.1186/s13063-016-1594-8>

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.



ERRATUM

Open Access



# Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'

Thomas P. Hellyer<sup>1\*</sup>, Niall H. Anderson<sup>2</sup>, Jennie Parker<sup>3</sup>, Paul Dark<sup>4</sup>, Tina Van Den Broeck<sup>5</sup>, Suveer Singh<sup>6</sup>, Ronan McMullan<sup>7</sup>, Ashley M. Agus<sup>8</sup>, Lydia M. Emerson<sup>9</sup>, Bronagh Blackwood<sup>9</sup>, Savita Gossain<sup>10</sup>, Tim S. Walsh<sup>11</sup>, Gavin D. Perkins<sup>12</sup>, Andrew Conway Morris<sup>13</sup>, Daniel F. McAuley<sup>2,8,14</sup> and A. John Simpson<sup>1</sup>

## Erratum

Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than  $10^4$  colony forming units/ml. These should read greater OR EQUAL to  $10^4$  colony forming units/ml. The error is in the abstract and in the intervention sections.

In the abstract, please replace:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at  $>10^4$  colony forming units per millilitre (CFU/ml).

With the following correct version:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at  $\geq 10^4$  colony forming units per millilitre (CFU/ml).

In the Interventions, please replace:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at  $>10^4$  colony forming units per ml (CFU/ml)(13).

With the following correct version:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at  $\geq 10^4$  colony forming units per ml (CFU/ml)(13).

## Author details

<sup>1</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. <sup>2</sup>Centre for Population Health Sciences, University of Edinburgh, Medical School, Edinburgh, UK. <sup>3</sup>Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK. <sup>4</sup>Institute of Inflammation and Repair, University of

Manchester, Manchester Academic Health Sciences Centre & Intensive Care Unit, Salford Royal NHS Foundation Trust, Greater Manchester, UK. <sup>5</sup>Becton Dickinson Biosciences, Erembodegem, Aalst, Belgium. <sup>6</sup>Intensive Care Unit, Chelsea and Westminster Hospital, Imperial College London, London, UK. <sup>7</sup>Department of Medical Microbiology, Kelvin Building, The Royal Hospitals, Belfast, UK. <sup>8</sup>Northern Ireland Clinical Trials Unit, Elliot Dunes Building, The Royal Hospitals, Belfast, UK. <sup>9</sup>Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK. <sup>10</sup>Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham, UK. <sup>11</sup>MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK. <sup>12</sup>University of Warwick and Heart of England NHS Foundation Trust, Coventry, UK. <sup>13</sup>Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. <sup>14</sup>Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.

Received: 30 August 2016 Accepted: 13 September 2016

Published online: 26 September 2016

## Reference

1. Hellyer TP, Anderson NH, Jennie P, Paul D, Tina Van Den B, Suveer S, Ronan MM, Agus AM, Emerson LM, Bronagh B, Savita G, Walsh TS, Perkins GD, Conway Morris A, McAuley DF, Simpson AJ. Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. *Trials*. 2016;17:318.

\* Correspondence: t.p.hellyer@ncl.ac.uk

<sup>1</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Full list of author information is available at the end of the article

